User:Zeteg/sandbox

Cell storage
There have been many developments with regards to iPSCs, and although there are still many problems and issues to be resolved, future medical treatments involving iPSCs seem more realistic. Regardless of their actual viability and stage of development, the private sector has begun capitalizing on the possibility of their mainstream use. One company, at least, has begun offering collection and storage services for iPSCs for the public, claiming that banking cells immediately helps to avoid de novo mutations. While cells can potentially undergo mutations and damage, iPSC technology is new, and there is not yet conducive evidence to support what exactly happens with iPSCs derived from older or mutated cells. Therefore, it is uncertain whether banking cells at a younger age is beneficial, even if the technology is developed to make use of these cells.

=Stem cell laws= It should be noted that the information presented here covers the legal implications of embryonic stem cells (ES), rather than induced pluripotent stem cells (iPSCs). The laws surrounding the two differ because while both have similar capacities in differentiation, their modes of derivation are not. While embryonic stem cells are taken from embryoblasts, induced pluripotent stem cells are undifferentiated from somatic adult cells.

Neural transplantation
Unfortunately, induced pluripotent stem cells are typically created through transcription factors. Some of these, which includes the typically used c-Myc areoncogenes. Thus, dopaminergic neurons differentiated from induced pluripotent stem cells have a higher chance of becoming cancerous. There has, however, been efforts to create induced pluripotent stem cells without the use of these reprogramming factors. There has been mild success, but such successes typically come with a trade off with efficacy.